Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Velvet Cichlid on its public offer for Sleep Cycle
Mandate

Vinge advises Velvet Cichlid on its public offer for Sleep Cycle

December 19, 2022 Life Sciences & Health

Velvet Cichlid has announced a public offer to the shareholders of Sleep Cycle AB (publ). The offer values the shares of Sleep Cycle at approximately SEK 862 million.

The Vinge team includes Jesper Schönbeck, Erik Sjöman, Linnéa Sellström, William Kåge, Emma Brolund, Philip Moré and Petter Hellgren (Capital Markets and Public M&A), Louise Brorsson Salomon and Seyran Sahin (Banking and Finance).

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026